Glaxo-Backed Vaccine Shows Strong Immune Response in Early Trial
This article is for subscribers only.
A Covid-19 vaccine project supported by GlaxoSmithKline Plc is headed for advanced trials after showing a strong immune response in early studies.
Sichuan Clover Biopharmaceuticals Inc. of China said its shot induced neutralizing antibodies and proved to be safe in a study of 150 adults and elderly volunteers. The vaccine uses adjuvants -- agents that boost a vaccine’s response -- from both Glaxo and Dynavax Technologies Corp.